AR082641A1 - Composiciones de anticuerpo anti-vegfr-3 - Google Patents

Composiciones de anticuerpo anti-vegfr-3

Info

Publication number
AR082641A1
AR082641A1 ARP110103100A ARP110103100A AR082641A1 AR 082641 A1 AR082641 A1 AR 082641A1 AR P110103100 A ARP110103100 A AR P110103100A AR P110103100 A ARP110103100 A AR P110103100A AR 082641 A1 AR082641 A1 AR 082641A1
Authority
AR
Argentina
Prior art keywords
seq
vegfr
antibodies
antibody compositions
antibody
Prior art date
Application number
ARP110103100A
Other languages
English (en)
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44584686&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082641(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of AR082641A1 publication Critical patent/AR082641A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente solicitud se refiere a anticuerpos monoclonales anti-VEGFR-3 (anti receptor del factor de crecimiento endotelial vascular 3), composiciones farmacéuticas que contienen los anticuerpos y usos de los anticuerpos en el tratamiento de enfermedades.Reivindicación 1: Un anticuerpo o porción del mismo enlazante al antígeno, caracterizado porque específicamente se une a VEGFR-3 humano que comprende un LCDR1 de la SEC ID Nº 2, una LCDR2 de la SEC ID Nº 2, una LCDR3 de la SEC ID Nº 3, una HCDR1 de la SEC ID Nº 6, una HCDR2 de la SEC ID Nº 7 y una HCDR3 de la SEC ID Nº 8.
ARP110103100A 2010-09-07 2011-08-25 Composiciones de anticuerpo anti-vegfr-3 AR082641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38043210P 2010-09-07 2010-09-07

Publications (1)

Publication Number Publication Date
AR082641A1 true AR082641A1 (es) 2012-12-19

Family

ID=44584686

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103100A AR082641A1 (es) 2010-09-07 2011-08-25 Composiciones de anticuerpo anti-vegfr-3

Country Status (25)

Country Link
US (2) US8481034B2 (es)
EP (1) EP2614081B1 (es)
JP (1) JP2013538813A (es)
KR (1) KR20130042601A (es)
CN (1) CN103080133A (es)
AR (1) AR082641A1 (es)
AU (1) AU2011299443B2 (es)
BR (1) BR112013005423A2 (es)
CA (1) CA2809375C (es)
CL (1) CL2013000607A1 (es)
CO (1) CO6690754A2 (es)
CR (1) CR20130065A (es)
DO (1) DOP2013000039A (es)
EA (1) EA023331B1 (es)
EC (1) ECSP13012481A (es)
ES (1) ES2568801T3 (es)
GT (1) GT201300058A (es)
MA (1) MA34487B1 (es)
MX (1) MX2013002718A (es)
PE (1) PE20131328A1 (es)
SG (1) SG188265A1 (es)
TW (1) TWI413527B (es)
UA (1) UA109148C2 (es)
WO (1) WO2012033696A1 (es)
ZA (1) ZA201300804B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014064203A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
KR101521981B1 (ko) * 2013-07-31 2015-05-20 가톨릭대학교 산학협력단 혈액암 줄기세포 증식 또는 생착 억제용 조성물
CN107405410B (zh) * 2015-01-15 2021-08-10 OncoQuest制药有限公司 增加抗癌剂向靶递送的方法
CN110004167A (zh) * 2019-04-16 2019-07-12 中国医学科学院血液病医院（血液学研究所） 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN111808191A (zh) * 2020-05-11 2020-10-23 廊坊天光生物技术有限公司 一种用于检测血清中vegf含量的抗体对及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1353952B1 (en) * 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies

Also Published As

Publication number Publication date
US20130280278A1 (en) 2013-10-24
BR112013005423A2 (pt) 2016-06-07
EA201390117A1 (ru) 2013-06-28
US20120058126A1 (en) 2012-03-08
CA2809375C (en) 2016-02-09
DOP2013000039A (es) 2013-04-15
ZA201300804B (en) 2014-07-30
US8481034B2 (en) 2013-07-09
TWI413527B (zh) 2013-11-01
ECSP13012481A (es) 2015-03-31
EA023331B1 (ru) 2016-05-31
CA2809375A1 (en) 2012-03-15
EP2614081A1 (en) 2013-07-17
WO2012033696A1 (en) 2012-03-15
CO6690754A2 (es) 2013-06-17
US8784818B2 (en) 2014-07-22
GT201300058A (es) 2014-07-16
TW201223543A (en) 2012-06-16
EP2614081B1 (en) 2016-03-16
MX2013002718A (es) 2013-05-01
UA109148C2 (uk) 2015-07-27
MA34487B1 (fr) 2013-08-01
CN103080133A (zh) 2013-05-01
SG188265A1 (en) 2013-04-30
PE20131328A1 (es) 2013-11-18
ES2568801T3 (es) 2016-05-04
AU2011299443B2 (en) 2014-06-05
CL2013000607A1 (es) 2014-04-11
CR20130065A (es) 2013-03-21
AU2011299443A1 (en) 2013-02-14
KR20130042601A (ko) 2013-04-26
JP2013538813A (ja) 2013-10-17

Similar Documents

Publication Publication Date Title
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
NZ603607A (en) Cgrp antibodies
CO6230999A2 (es) Anticuerpo anti-esclerostina
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
NZ729913A (en) St2l antagonists and methods of use
NZ628943A (en) Human antibodies to clostridium difficile toxins
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20141151A1 (es) Proteinas de union al antigeno cd27l
AR103713A1 (es) Anticuerpos contra tau y sus usos
RU2015110981A (ru) Комбинации и их применение

Legal Events

Date Code Title Description
FB Suspension of granting procedure